Clinical Trials Arena on MSN
AiCuris reports positive Phase III pritelivir results for HSV patients
The trial enrolled and treated 101 immunocompromised patients with refractory or resistant HSV infection.
Herpes is one of the most common viral infections in the world, yet it remains widely misunderstood. Caused by the herpes ...
Pritelivir met its primary endpoint of superior lesion healing, achieving a 62.7% lesion healing rate compared to 34.0% with standard-of-care ...
Investigational antiviral pritelivir demonstrates efficacy and improved tolerability over current treatments for refractory HSV in high-risk patients.
Genital herpes infections are very common. There are 42 million new infections each year — that averages out to one new person infected each second. While treatments can help with symptoms, there's no ...
Add Yahoo as a preferred source to see more of our stories on Google. man holding a hand ove rhis mouth A new study has confirmed genital herpes is the most common sexually transmitted infection (STI) ...
People diagnosed with HSV-1 infection had a higher risk of a subsequent Alzheimer's diagnosis. Antiherpetic drugs reduced Alzheimer's risk in those diagnosed with HSV-1. The findings apply only to ...
Around 846 million people aged between 15 and 49 are living with genital herpes infections – more than 1 in 5 of this age-group globally – according to new estimates released today. At least 1 person ...
The incidence of neonatal herpes simplex virus (HSV) infections in the UK and Ireland increased dramatically over 15 years, and outcomes remained poor, with mortality and long-term neurologic ...
A major UK clinical trial has shown that adding the corticosteroid dexamethasone to standard antiviral treatment for encephalitis (brain inflammation) caused by herpes simplex virus (HSV) does not ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results